Pre-registration will open in early 2026.
Pre-registration will open in early 2026.
Following an independent expert review, we have formally nominated the broad-spectrum pan-coronavirus antiviral ASAP-0017445 as a pre-clinical drug candidate.
🔗Read the press release here: dndi.org/press-releas...
Following an independent expert review, we have formally nominated the broad-spectrum pan-coronavirus antiviral ASAP-0017445 as a pre-clinical drug candidate.
🔗Read the press release here: dndi.org/press-releas...
I've been privileged to follow along since then (cen.acs.org/pharmaceutic...).
Congratulations to everyone who contributed.
I've been privileged to follow along since then (cen.acs.org/pharmaceutic...).
Congratulations to everyone who contributed.
Read about their important work here:
health.mountsinai.org/blog/stories...
Read about their important work here:
health.mountsinai.org/blog/stories...
From Edward Tufte & graphics.wsj.com/infectious-d...
From Edward Tufte & graphics.wsj.com/infectious-d...
Click for the full gov.uk article and direct quote from our Technical Director @griffen-ed.bsky.social
www.gov.uk/government/n...
🎥 Watch the recordings: www.youtube.com/playlist?lis...
📄 Access the slides: zenodo.org/communities/...
🎥 Watch the recordings: www.youtube.com/playlist?lis...
📄 Access the slides: zenodo.org/communities/...
@asapdiscovery.bsky.social
at: health.ec.europa.eu/events/hera-... #HealthUnion
@asapdiscovery.bsky.social
at: health.ec.europa.eu/events/hera-... #HealthUnion
Our Intellectual Property & Access Leader shares why, together with our partners from the @asapdiscovery.bsky.social, we are filing a #patent for a promising new #molecule that we developed together.
shorturl.at/IgL80
🔗 shorturl.at/gMY0t
🔗 shorturl.at/gMY0t
resist.bot/petitions/PX...
resist.bot/petitions/PX...
acs.digitellinc.com/live/34/sess...
acs.digitellinc.com/live/34/sess...
acs.digitellinc.com/live/34/sess...
@griffen-ed.bsky.social is presenting at #ICAR2025 the highlights of the discovery, in vitro and in vivo profile of the ASAP AViIDD Center’s pre-clinical candidate for treating 6 lethal coronavirus infections: ASAP-0017445. Register now 🔗 lnkd.in/gbBRZSz2 @asapdiscovery.bsky.social
@griffen-ed.bsky.social is presenting at #ICAR2025 the highlights of the discovery, in vitro and in vivo profile of the ASAP AViIDD Center’s pre-clinical candidate for treating 6 lethal coronavirus infections: ASAP-0017445. Register now 🔗 lnkd.in/gbBRZSz2 @asapdiscovery.bsky.social
@griffen-ed.bsky.social is presenting at the @conscience-network.bsky.social Symposium. Talk Title; "Balancing Open Science and Intellectual Property to Discover and Develop Medicines” @asapdiscovery.bsky.social
Register now: conscience.ca/symposium202...
@griffen-ed.bsky.social is presenting at the @conscience-network.bsky.social Symposium. Talk Title; "Balancing Open Science and Intellectual Property to Discover and Develop Medicines” @asapdiscovery.bsky.social
Register now: conscience.ca/symposium202...